Skip to main content
    G

    Galectin Therapeutics Inc (GALT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.71
    +0.07 (+1.92%)

    Market Cap: $367.09M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(26/39)
    Avg Surprise
    +1.62%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.05
    Range$-0.05 - $-0.05
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.10+50.0%
    60d ago$-0.10+50.0%
    30d ago$-0.10+50.0%
    7d ago$-0.10+50.0%
    Current$-0.05
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.10
    Range$-0.10 - $-0.10
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.10---
    Sep 26EST
    		-$-0.05---
    Jun 26
    Reported Aug 14
    		$-0.14$-0.09-55.56%Miss-16.7%
    Mar 26
    Reported May 15
    		$-0.08$-0.06-33.33%Miss+46.7%
    Dec 25
    Reported Mar 31
    		$-0.08$-0.10+20.00%Beat+57.9%
    Sep 25
    Reported Nov 14
    		$-0.13$-0.11-18.18%Miss+27.8%
    Jun 25
    Reported Aug 14
    		$-0.12$-0.16+25.00%Beat+40.0%
    Mar 25
    Reported May 15
    		$-0.15$-0.11-36.36%Miss+21.1%
    Dec 24
    Reported Mar 31
    		$-0.19$-0.16-18.75%Miss-18.8%
    Sep 24
    Reported Nov 14
    		$-0.18$-0.20+10.00%Beat+25.0%
    Jun 24
    Reported Aug 13
    		$-0.20$-0.16-25.00%Miss-33.3%
    Mar 24
    Reported May 15
    		$-0.19$-0.16-18.75%Miss+0.0%
    Dec 23
    Reported Mar 29
    		$-0.16$-0.16+0.00%Beat+11.1%
    Sep 23
    Reported Nov 13
    		$-0.24$-0.16-50.00%Miss-71.4%
    Jun 23
    Reported Aug 14
    		$-0.15$-0.21+28.57%Beat+6.3%
    Mar 23
    Reported May 15
    		$-0.19$-0.21+9.52%Beat-11.8%
    Dec 22
    Reported Mar 30
    		$-0.18$-0.17-5.88%Miss-50.0%
    Sep 22
    Reported Nov 14
    		$-0.14$-0.20+30.00%Beat+0.0%
    Jun 22
    Reported Aug 15
    		$-0.16$-0.19+15.79%Beat-6.7%
    Mar 22
    Reported May 16
    		$-0.17$-0.14-21.43%Miss-54.5%
    Dec 21
    Reported Mar 31
    		$-0.12$-0.19+36.84%Beat+7.7%
    Sep 21
    Reported Nov 15
    		$-0.14$-0.18+22.22%Beat-40.0%
    Jun 21
    Reported Aug 16
    		$-0.15$-0.18+16.67%Beat-36.4%
    Mar 21
    Reported May 17
    		$-0.11$-0.17+35.29%Beat-83.3%
    Dec 20
    Reported Mar 31
    		$-0.13$-0.16+18.75%Beat-8.3%
    Sep 20
    Reported Nov 9
    		$-0.10$-0.14+28.57%Beat-100.0%
    Jun 20
    Reported Aug 10
    		$-0.11$-0.07-57.14%Miss-83.3%
    Mar 20
    Reported May 11
    		$-0.06$-0.09+33.33%Beat+70.0%
    Dec 19
    Reported Mar 16
    		$-0.12$-0.06-100.00%Miss-50.0%
    Sep 19
    Reported Nov 12
    		$-0.05$-0.10+50.00%Beat+28.6%
    Jun 19
    Reported Aug 9
    		$-0.06$-0.12+50.00%Beat+45.5%
    Mar 19
    Reported May 10
    		$-0.20$-0.14-42.86%Miss-66.7%
    Dec 18
    Reported Mar 6
    		$-0.08$-0.08+0.00%Beat-14.3%
    Sep 18
    Reported Nov 13
    		$-0.07$-0.09+22.22%Beat+46.2%
    Jun 18
    Reported Aug 14
    		$-0.11$-0.11+0.00%Beat+21.4%
    Mar 18
    Reported May 11
    		$-0.12$-0.13+7.69%Beat+20.0%
    Dec 17
    Reported Mar 29
    		$-0.07$-0.11+36.36%Beat+41.7%
    Sep 17
    Reported Nov 7
    		$-0.13$-0.15+13.33%Beat-
    Jun 17
    Reported Aug 14
    		$-0.14$-0.15+6.67%Beat-
    Mar 17
    Reported May 15
    		$-0.15$-0.15+0.00%Beat-
    Dec 16
    Reported Mar 28
    		$-0.12$-0.17+29.41%Beat-

    Key Metrics

    Valuation
    P/E Ratio-8.63EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-3728.00%ROIC15.14%
    Financial Health
    Debt/Equity-0.24xInterest Coverage-2.61x
    Current Ratio0.10xQuick Ratio0.10x
    Trading Statistics
    Beta0.38Avg Volume252.06K
    52-Week High$7.1352-Week Low$2.03

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.75
    SMA 20$3.84
    SMA 50$3.81
    SMA 200$3.21
    EMA 10$3.76
    EMA 20$3.80
    EMA 50$3.78
    EMA 200$3.49

    MACD

    Line: -0.05Signal: -0.03Hist: -0.02

    ADX

    ADX: 14.0+DI: 18.3-DI: 22.5

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down80.0
    PSAR$4.00

    Bollinger Bands

    Upper Band$4.13
    Lower Band$3.56
    %B Position1492%(Upper)
    Band Width0.27

    RSI (14-Day)

    Neutral
    46.3

    Momentum Oscillators

    Stoch %K31.2
    Stoch %D39.4
    Williams %R-63.3
    ROC (10d)-1.3%
    Momentum-0.05
    CCI (20d)-72.5
    MFI (14d)25.7

    Volatility Measures

    ATR (14d)$0.24(6.4%)
    StdDev (20d)0.14
    Hist Vol53.6%(High)

    Volume Flow

    VWAP$3.74
    OBV20.0M
    AD Line2.6M
    CMF (20d)0.046

    Volume Metrics

    Avg Vol (20d)254.9K
    Vol Ratio0.5x(Low)
    VWMA (20d)$3.84

    Pivot Points

    R3$4.05
    R2$3.95
    R1$3.80
    Pivot Point$3.70
    S1$3.55
    S2$3.45
    S3$3.30

    Advanced Oscillators

    TSI-5.75
    Ultimate Osc39.4
    KST-31.23

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$36,000$0$0$0$80,000$0
    Cost of Revenue$0$0$-12,000$0$0$0$10,000$0$0$0$9,000$0
    Gross Profit$0$0$12,000$0$0$0$-10,000$0$0$0$-9,000$0
    Operating Expenses$3.98M$4.08M$3.37M$4.20M$4.63M$7.90M$12.43M$9.07M$11.29M$9.65M$9.56M$9.17M
    R&D$2.13M$2.23M$1.93M$2.61M$3.26M$6.49M$11.11M$7.59M$9.81M$8.05M$8.23M$7.73M
    SG&A$1.85M$1.85M$1.43M$1.59M$1.36M$1.41M$1.32M$1.47M$1.48M$1.59M$1.33M$1.43M
    Operating Income$-3,982,000$-4,077,000$-3,365,000$-4,198,000$-4,625,000$-7,897,000$-12,428,000$-9,066,000$-11,291,000$-9,648,000$-9,561,000$-9,166,000
    Interest Income$28,000$36,000$26,000$39,000$26,000$35,000$85,000$93,000$80,000$80,000$74,000$62,000
    Interest Expense$2.00M$1.99M$1.94M$1.82M$1.83M$1.74M$1.73M$1.49M$1.27M$1.05M$847,000$835,000
    Income Before Tax$-9,113,000$-5,046,000$-5,500,000$-8,184,000$-7,521,000$-9,631,000$-11,967,000$-11,220,000$-12,371,000$-11,489,000$-9,997,000$-10,428,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-9,113,000$-5,046,000$-5,500,000$-8,184,000$-7,521,000$-9,631,000$-11,967,000$-11,220,000$-12,371,000$-11,489,000$-9,997,000$-10,428,000
    EBITDA$-7,133,000$-3,082,000$-3,546,000$-6,403,000$-5,719,000$-7,912,000$-10,317,000$-9,810,000$-11,182,000$-10,517,000$-9,215,000$-9,647,000
    EBIT$-7,137,000$-3,094,000$-3,587,000$-6,403,000$-5,721,000$-7,922,000$-10,327,000$-9,819,000$-11,182,000$-10,517,000$-9,224,000$-9,655,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GALT

    News

    Galectin Therapeutics Reports Fiscal Year 2025 10-K Highlighting Belapectin Clinical Progress

    Galectin Therapeutics has filed its Annual Report on Form 10-K for the fiscal year ending December 31, 2025, detailing the ongoing clinical development of its lead drug candidate...

    Kalkine Media•10/13/26•Bullish

    Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above Two Hundred Day Moving Average - Here's Why

    Galectin Therapeutics (NASDAQ:GALT) shares recently crossed above their 200-day moving average, reaching $3.86 before closing at $3.62, significantly higher than the $3.25 average. Analyst sentiment on GALT is mixed...

    MarketBeat•10/8/26•Neutral

    Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026

    Galectin Therapeutics (NASDAQ: GALT) announced its participation in the AASLD Liver Meeting 2026, featuring three presentations on belapectin for MASH cirrhosis and portal hypertension. The company will deliver an oral...

    The Manila Times•10/7/26•Bullish

    Galectin Therapeutics stock gets a Phase 3 protocol update

    Galectin Therapeutics (GALT) submitted its registrational Phase 3 protocol for belapectin to the FDA on October 6, 2026, causing its stock to decline by 4.36%. The trial will study belapectin in MASH cirrhosis patients...

    AD HOC NEWS•10/6/26•Neutral

    Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026

    Galectin Therapeutics will deliver three presentations, including an oral presentation and a Poster of Distinction, at the AASLD Liver Meeting 2026...

    Yahoo Finance•10/6/26•Bullish

    GALT Valuation and Fair Value

    P/E
    -8.6x
    Forward P/E
    4.5x
    PEG
    0.0x
    P/B
    -1.8x
    See GNG's fair value

    GALT Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    15.1%
    ROE
    -3728.0%

    GALT Competitors

    CompanyTicker
    Wellgistics Health, Inc. Common StockWGRX
    Fennec Pharmaceuticals IncFENC
    Viemed Healthcare IncVMD
    Emergent Biosolutions IncEBS
    Orthofix Medical IncOFIX
    Kyverna Therapeutics, Inc. Common StockKYTX
    Simulations Plus IncSLP
    Embecta CorpEMBC

    Sector: Healthcare

    GALT Bull Case vs Bear Case

    Bull case

    • GALT earns a 15.1% return on invested capital.

    Bear case

    • GALT beat EPS estimates in 37.5% of its last 8 reported quarters.

    GALT Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -13.4%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.05
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About GALT

    Does GALT pay dividends?

    Galectin Therapeutics Inc (GALT) does not currently pay a regular dividend.

    What is GALT's market cap?

    Galectin Therapeutics Inc (GALT) has a market capitalization of $367.09M with a current stock price of $3.71.

    Related stocks

    Sector: Healthcare

    All stocks starting with G

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In